Citius Pharmaceuticals (CTXR) Sidoti Micro-Cap Virtual Conference summary

Strategic highlights and portfolio developments

• Leadership has invested significant personal capital, reflecting strong confidence in the portfolio.

• FDA approval received for LYMPHIR, a treatment for cutaneous T-cell lymphoma, with launch planned for early 2025.

• Mino-Lok completed a successful phase 3 trial for catheter-related bloodstream infections, targeting a $2 billion market.

• Halo-Lido, a potential first-in-class prescription hemorrhoid treatment, is being positioned for monetization.

• Citius Oncology (CTOR) was spun off and began trading in August 2024, with 90% ownership retained.

Product pipeline and market opportunities

• LYMPHIR targets a $300–$400 million market and is being studied in combination with KEYTRUDA and CAR T therapies.

• Investigator-initiated trials may expand LYMPHIR's indications, including peripheral T-cell lymphoma.

• Mino-Lok is the only product in its market, with QIDP status granting over nine years of exclusivity.

• Halo-Lido aims to address an unmet need as the first FDA-approved prescription for grades 2–4 hemorrhoids.

Financials, funding, and corporate structure

• $17.9 million in cash as of June 30, 2024, following a capital raise in April.

• Announced a $50 million at-the-market offering for future funding needs, with no warrants attached.

• CTOR's NASDAQ listing enables rapid fundraising for oncology initiatives, with financial results consolidated.

• Both CTXR and CTOR will continue as separate, publicly traded entities.